Table 3.
Univariate and multivariate analysis for overall survival of major prognostic factors
|
Prognostic factor |
Category |
n |
Median (months) |
Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p value* | Hazard ratio | 95% CI | p value** | ||||
| Age (years) |
≦ 70 |
43 |
17.0 |
1.00 |
0.35 - 1.03 |
0.062 |
|
|
|
| >70 |
35 |
22.7 |
0.60 |
|
|
|
|||
| PSA at DTX initiation (ng/ml) |
≦ 20 |
39 |
39.6 |
1.00 |
1.94 - 6.11 |
<0.001 |
1.00 |
|
0.058 |
| >20 |
39 |
12.6 |
3.44 |
2.07 |
0.98 - 4.37 |
|
|||
| PSADT (months) |
>2.4 |
38 |
31.4 |
1.00 |
1.48 - 4.41 |
0.001 |
1.00 |
|
0.033 |
| ≦ 2.4 |
40 |
16.7 |
2.56 |
1.88 |
1.05 - 3.36 |
|
|||
| ECOG performance status |
≦ 1 |
68 |
20.3 |
1.00 |
1.55 - 6.26 |
0.001 |
1.00 |
|
0.740 |
| 2 |
10 |
4.1 |
3.11 |
1.16 |
0.49 - 2.74 |
|
|||
| Gleason score |
≦ 7 |
21 |
31.2 |
1.00 |
0.89 - 3.00 |
0.113 |
|
|
|
| >8 |
57 |
18.2 |
1.63 |
|
|
|
|||
| Armstrong risk classification |
Good |
51 |
30.1 |
1.00 |
|
|
1.00 |
|
0.060 |
| Intermediate |
17 |
14.2 |
2.48 |
1.32 - 4.66 |
<0.001 |
1.33 |
0.60 - 2.97 |
0.487 |
|
| Poor | 10 | 5.7 | 6.58 | 3.07 - 14.11 | 3.21 | 1.17 - 8.80 | 0.024 | ||
Abbreviations: CI, confidence interval; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase. *log rank test. **Cox proportional hazards model.